Intensity Therapeutics rises on positive breast-cancer study data

Intensity Therapeutics

08/12/2023 15:29

** Shares of Intensity Therapeutics  INTS.O  up 134% in
morning trade to an all-time high of $11.09
    ** Co says its lead drug candidate INT230-6 killed more than
95% of cancerous tumors in a mid-stage study evaluating it as a
potential treatment for early-stage breast cancer
    ** The drug candidate is being tested with Merck's  MRK.N 
blockbuster cancer immunotherapy Keytruda and Bristol-Myers
Squibb's  BMY.N  cancer drug Yervoy for various cancers
    ** INTS has completed various early and mid-stage trials of
INT-230-6, either as a lone drug or as a combination treatment
    ** Co expects to apply for clearance to start a late-stage
study in soft tissue cancer in the "near-term"
    ** Including session gain, stock up 85% from its IPO price
of $5; stock was listed on Nasdaq in June

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))